Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;2(3):174-181.
doi: 10.1007/s13670-013-0056-3.

Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics

Lawrence S Honig  1 , Clara D Boyd
Affiliations

Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics

Lawrence S Honig et al. Curr Transl Geriatr Exp Gerontol Rep. 2013 Sep.

Abstract

Alzheimer's disease (AD) is a major cause of morbidity in the elderly. AD affects aver 5 million persons in the United States, but because it increases in incidence in the elderly, and the "graying" population, AD is projected to increase in prevalence by many-fold over the coming decades. AD causes progressive mental impairment, resulting in the inability of persons to care for themselves. As a consequence, AD results in enormous costs to society due to both lost productivity, and required care. Thus, improved management and treatment is essential. In this review we will briefly review current understanding of the disease, including roles of beta-amyloid and tau proteins. We will then discuss current therapies in use, including the evidence for treatments with supplements, established drugs, and investigational therapeutic strategies, recently completed and ongoing.

Keywords: Alzheimer’s disease; Amyloid; Anti-amyloid; Beta-amyloid; Beta-secretase; Cholinesterase; Dementia; Elderly; Experimental therapeutics; Gamma-secretase; Monoclonal antibody; Phosphotau; Secretase; Tau; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Lawrence S. Honig has served as a consultant for Johnson & Johnson/Janssen Pharmaceutica and has received grant support from Genentech, Johnson & Johnson/Janssen Pharmaceutica, Eli Lilly and Company, Bristol-Myers Squibb, and Pfizer.

References

    1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the united states (2010–2050) estimated using the 2010 census. Neurology. 2013 - PMC - PubMed
    1. Schneider LS. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn) 2013;19(2 Dementia):339–357. - PMC - PubMed
    1. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68(1):1–14. - PMC - PubMed
    1. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature medicine. 2006;12(7):856–861. - PMC - PubMed
    1. Small SA, Gandy S. Sorting through the cell biology of alzheimer’s disease: Intracellular pathways to pathogenesis. Neuron. 2006;52(1):15–31. - PMC - PubMed

LinkOut - more resources